Cerus Corporation (CERS) and Catalyst Biosciences Inc. (NASDAQ:CBIO) Contrasting side by side

Cerus Corporation (NASDAQ:CERS) and Catalyst Biosciences Inc. (NASDAQ:CBIO) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cerus Corporation 4 0.00 128.27M -0.46 0.00
Catalyst Biosciences Inc. 5 0.05 7.15M -3.36 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 represents Cerus Corporation (NASDAQ:CERS) and Catalyst Biosciences Inc. (NASDAQ:CBIO)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Cerus Corporation 2,954,372,711.15% -74.3% -38.3%
Catalyst Biosciences Inc. 130,952,380.95% -32.6% -31.5%

Risk & Volatility

Cerus Corporation’s volatility measures that it’s 60.00% more volatile than Standard and Poor’s 500 due to its 1.6 beta. Catalyst Biosciences Inc.’s 88.00% more volatile than Standard and Poor’s 500 which is a result of the 1.88 beta.


The Current Ratio and a Quick Ratio of Cerus Corporation are 2.8 and 2.5. Competitively, Catalyst Biosciences Inc. has 24.9 and 24.9 for Current and Quick Ratio. Catalyst Biosciences Inc.’s better ability to pay short and long-term obligations than Cerus Corporation.

Analyst Recommendations

Cerus Corporation and Catalyst Biosciences Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cerus Corporation 0 0 2 3.00
Catalyst Biosciences Inc. 0 0 0 0.00

Cerus Corporation has a 78.78% upside potential and a consensus price target of $7.5.

Insider and Institutional Ownership

The shares of both Cerus Corporation and Catalyst Biosciences Inc. are owned by institutional investors at 69.1% and 82.9% respectively. Insiders held roughly 2.1% of Cerus Corporation’s shares. Comparatively, 0.4% are Catalyst Biosciences Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cerus Corporation 0.17% 8.74% -4.57% 2.27% -18.52% 15.38%
Catalyst Biosciences Inc. -1.92% 10.38% -5.43% -4.21% -15.39% 3.8%

For the past year Cerus Corporation has stronger performance than Catalyst Biosciences Inc.


Cerus Corporation beats on 6 of the 11 factors Catalyst Biosciences Inc.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was founded in 1991 and is headquartered in Concord, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.